Related Experiment Video

Updated: Sep 3, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation

Nikolaos Karamichalakis1, Vasileios Kolovos1, Ioannis Paraskevaidis1

  • 16th Department of Cardiology, Hygeia Hospital, 15123 Athens, Greece.

Journal of Cardiovascular Development and Disease
|July 27, 2022
PubMed

Insights

Diabetes mellitus (DM) increases the risk of atrial arrhythmias like atrial fibrillation (AF). Sodium-glucose cotransporter-2 inhibitors (SGLT2is) show a protective effect against AF and atrial flutter (AFl) in patients with DM.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Atrial arrhythmias, including atrial fibrillation (AF) and atrial flutter (AFl), are prevalent in patients with diabetes mellitus (DM).
  • Despite advancements in treatment, these conditions remain significant causes of mortality and morbidity.
  • Existing treatments for DM-related atrial arrhythmias have limitations.

Purpose of the Study:

  • To review the mechanisms linking diabetes mellitus to atrial arrhythmia genesis and recurrence.
  • To evaluate the protective effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on AF and AFl occurrence.
  • To synthesize current knowledge from experimental studies, clinical trials, and meta-analyses.

Main Methods:

  • Literature review of experimental studies on DM-mediated mechanisms.
  • Analysis of published clinical trials investigating SGLT2is.
  • Synthesis of data from meta-analyses concerning SGLT2is and atrial arrhythmias.

Main Results:

  • Diabetes mellitus contributes to the development and persistence of atrial arrhythmias through specific pathophysiological pathways.
  • Clinical trial data suggest a protective role for SGLT2 inhibitors in preventing AF and AFl.
  • Meta-analyses corroborate the beneficial effects of SGLT2is in this patient population.

Conclusions:

  • Understanding DM-mediated mechanisms is crucial for managing atrial arrhythmias.
  • SGLT2 inhibitors represent a promising therapeutic strategy for reducing the incidence of AF and AFl in diabetic patients.
  • Further research should explore the full potential of SGLT2is in cardiovascular protection in DM.
Keywords:
atrial fibrillationatrial flutterdiabetes mellitussodium-glucose cotransporter-2 inhibitors

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
247
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
122.9K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
830
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
32.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K